Yale Cancer Center
@yalecancer.bsky.social
Yale Cancer Center is a collaboration between renowned cancer researchers and physicians at Yale University and Smilow Cancer Hospital.
De. Jensa Morris joins #YaleCancerAnswers tonight at 7:30pm to talk about the critical role #hospitalists play in #cancer care and helping patients recover faster + spend less time in the hospital.
🎧Listen live on #WNPR
🔁Download #ApplePodcasts
💻Watch on #YouTube
🎧Listen live on #WNPR
🔁Download #ApplePodcasts
💻Watch on #YouTube
December 28, 2025 at 6:59 PM
De. Jensa Morris joins #YaleCancerAnswers tonight at 7:30pm to talk about the critical role #hospitalists play in #cancer care and helping patients recover faster + spend less time in the hospital.
🎧Listen live on #WNPR
🔁Download #ApplePodcasts
💻Watch on #YouTube
🎧Listen live on #WNPR
🔁Download #ApplePodcasts
💻Watch on #YouTube
Dr. Roy Herbst commented on #TheLead with #JakeTapper:
"When #lungcancer is found early, and we use all different modalities bringing surgery, radiation and all scientific advances together, the prognosis can be quite good." #BarryManilow @yaleschoolofmed.bsky.social
"When #lungcancer is found early, and we use all different modalities bringing surgery, radiation and all scientific advances together, the prognosis can be quite good." #BarryManilow @yaleschoolofmed.bsky.social
December 23, 2025 at 1:35 PM
Dr. Roy Herbst commented on #TheLead with #JakeTapper:
"When #lungcancer is found early, and we use all different modalities bringing surgery, radiation and all scientific advances together, the prognosis can be quite good." #BarryManilow @yaleschoolofmed.bsky.social
"When #lungcancer is found early, and we use all different modalities bringing surgery, radiation and all scientific advances together, the prognosis can be quite good." #BarryManilow @yaleschoolofmed.bsky.social
Join us Wednesday, Jan. 28 at 6pm for a free networking and #CME dinner on women's health + #breastcancer.
Presenters include Drs. Robert Legare, Anca Bulgaru, Mary Jane Minkin, Jill Banatoski, and @maryamlustberg.bsky.social.
➡️RSVP bit.ly/48QFOcc
Presenters include Drs. Robert Legare, Anca Bulgaru, Mary Jane Minkin, Jill Banatoski, and @maryamlustberg.bsky.social.
➡️RSVP bit.ly/48QFOcc
December 22, 2025 at 1:47 PM
Join us Wednesday, Jan. 28 at 6pm for a free networking and #CME dinner on women's health + #breastcancer.
Presenters include Drs. Robert Legare, Anca Bulgaru, Mary Jane Minkin, Jill Banatoski, and @maryamlustberg.bsky.social.
➡️RSVP bit.ly/48QFOcc
Presenters include Drs. Robert Legare, Anca Bulgaru, Mary Jane Minkin, Jill Banatoski, and @maryamlustberg.bsky.social.
➡️RSVP bit.ly/48QFOcc
Tonight on #YaleCancerAnswers, Dr. Daniel O'Neil discusses the latest research on improving #breastcancer outcomes in low-middle income countries.
🔸Listen live on WNPR
🔸Download via Apple Podcasts
🔸Watch on YouTube
🔸Listen live on WNPR
🔸Download via Apple Podcasts
🔸Watch on YouTube
December 21, 2025 at 10:04 PM
Tonight on #YaleCancerAnswers, Dr. Daniel O'Neil discusses the latest research on improving #breastcancer outcomes in low-middle income countries.
🔸Listen live on WNPR
🔸Download via Apple Podcasts
🔸Watch on YouTube
🔸Listen live on WNPR
🔸Download via Apple Podcasts
🔸Watch on YouTube
Dr. Roy Herbst stopped by the Yale Medical Oncology-Hematology Fellows' holiday dinner last night to deliver some holiday cheer!
December 19, 2025 at 8:56 PM
Dr. Roy Herbst stopped by the Yale Medical Oncology-Hematology Fellows' holiday dinner last night to deliver some holiday cheer!
The #WISDOM study looked at risk-based screening for #breastcancer + results were presented at #SABCS25.
Dr. Eric Winer: "It is practice-changing, and I think it has huge public health implications.”
➡️ www.nytimes.com/2025/12/12/h...
Dr. Eric Winer: "It is practice-changing, and I think it has huge public health implications.”
➡️ www.nytimes.com/2025/12/12/h...
Risk-Based Screening Works as Well as Yearly Checks After 40 in Finding Breast Cancers
www.nytimes.com
December 18, 2025 at 9:03 PM
The #WISDOM study looked at risk-based screening for #breastcancer + results were presented at #SABCS25.
Dr. Eric Winer: "It is practice-changing, and I think it has huge public health implications.”
➡️ www.nytimes.com/2025/12/12/h...
Dr. Eric Winer: "It is practice-changing, and I think it has huge public health implications.”
➡️ www.nytimes.com/2025/12/12/h...
Congratulations to Dr. Shilpa Murthy, recipient of a Defense Health Agency Career Development Award!
medicine.yale.edu/news-article...
@pamelakunzmd.bsky.social
medicine.yale.edu/news-article...
@pamelakunzmd.bsky.social
Dr. Shilpa S. Murthy Receives 1.1 Million DoD Career Development Award
Shilpa S. Murthy, MD, MPH, an early career investigator at Yale Cancer Center and an assistant professor of surgery in the Division of Colon and Rectal Surgery
medicine.yale.edu
December 16, 2025 at 1:27 PM
Congratulations to Dr. Shilpa Murthy, recipient of a Defense Health Agency Career Development Award!
medicine.yale.edu/news-article...
@pamelakunzmd.bsky.social
medicine.yale.edu/news-article...
@pamelakunzmd.bsky.social
Reposted by Yale Cancer Center
Join us for #Pathology Grand Rounds on Thursday, Dec. 18 at 12:30 PM ET as W. Fraser Symmans, MBChB, of @mdanderson.bsky.social, presents on, “Prognosis & Prediction in Adjuvant Treatment of Hormone Receptor-Positive Breast Cancer’ @yaleschoolofmed.bsky.social @yalecancer.bsky.social bit.ly/4pDVhDG
December 15, 2025 at 1:12 PM
Join us for #Pathology Grand Rounds on Thursday, Dec. 18 at 12:30 PM ET as W. Fraser Symmans, MBChB, of @mdanderson.bsky.social, presents on, “Prognosis & Prediction in Adjuvant Treatment of Hormone Receptor-Positive Breast Cancer’ @yaleschoolofmed.bsky.social @yalecancer.bsky.social bit.ly/4pDVhDG
Congratulations to @maryamlustberg.bsky.social, named by
@oncodaily.bsky.social as one of the 100 Influential Women in Oncology to follow on social media in 2025! oncodaily.com/community/10...
@oncodaily.bsky.social as one of the 100 Influential Women in Oncology to follow on social media in 2025! oncodaily.com/community/10...
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025 - OncoDaily
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025 / 100 Influential Women, 100 Influential Women in Oncology, 1000
oncodaily.com
December 15, 2025 at 5:37 PM
Congratulations to @maryamlustberg.bsky.social, named by
@oncodaily.bsky.social as one of the 100 Influential Women in Oncology to follow on social media in 2025! oncodaily.com/community/10...
@oncodaily.bsky.social as one of the 100 Influential Women in Oncology to follow on social media in 2025! oncodaily.com/community/10...
Dr. Luisa Escobar-Hoyos was awarded the 2025 Dr. Ralph and Marian Falk Medical Research Trust Transformational Award which includes a $1M grant to support her team’s #pancreaticcancer research.
medicine.yale.edu/news-article...
medicine.yale.edu/news-article...
Assistant Professor Luisa Escobar-Hoyos Receives Prestigious Medical Research Award
Luisa Escobar-Hoyos, MSc, PhD, an assistant professor in the Departments of Therapeutic Radiology, Molecular Biophysics and Biochemistry, and Medicine, has been
medicine.yale.edu
December 15, 2025 at 5:34 PM
Dr. Luisa Escobar-Hoyos was awarded the 2025 Dr. Ralph and Marian Falk Medical Research Trust Transformational Award which includes a $1M grant to support her team’s #pancreaticcancer research.
medicine.yale.edu/news-article...
medicine.yale.edu/news-article...
Dr. Patricia LoRusso joins #YaleCancerAnswers at 7:30pm to discuss #cancer breakthroughs that made headlines in 2025, and how new therapies move from #clinicaltrials ➡️ FDA approvals.
🎧Listen live on WNPR
🔁Download Apple Podcasts
💻Watch on YouTube
@theaacr.bsky.social
🎧Listen live on WNPR
🔁Download Apple Podcasts
💻Watch on YouTube
@theaacr.bsky.social
December 14, 2025 at 6:32 PM
Dr. Patricia LoRusso joins #YaleCancerAnswers at 7:30pm to discuss #cancer breakthroughs that made headlines in 2025, and how new therapies move from #clinicaltrials ➡️ FDA approvals.
🎧Listen live on WNPR
🔁Download Apple Podcasts
💻Watch on YouTube
@theaacr.bsky.social
🎧Listen live on WNPR
🔁Download Apple Podcasts
💻Watch on YouTube
@theaacr.bsky.social
Drs. Jessica Liu and Guannan Gong present new data #SABCS25 showing automated #ClinicalTrial Patient Matching (CTPM) helps identify diverse trial candidates, but additional strategies are needed to boost participation. @maryamlustberg.bsky.social
December 12, 2025 at 1:53 AM
Drs. Jessica Liu and Guannan Gong present new data #SABCS25 showing automated #ClinicalTrial Patient Matching (CTPM) helps identify diverse trial candidates, but additional strategies are needed to boost participation. @maryamlustberg.bsky.social
De. Adam Krysztofiak shares how HER2-targeted triplex-forming oligonucleotides (TFOs) cause DNA damage + trigger cell death in HER2+ #breastcancer cells. They turn on the immune system, offering a new way to improve responses + overcome resistance to HER2 therapies. #sabcs @oncoalert.bsky.social
December 12, 2025 at 1:51 AM
De. Adam Krysztofiak shares how HER2-targeted triplex-forming oligonucleotides (TFOs) cause DNA damage + trigger cell death in HER2+ #breastcancer cells. They turn on the immune system, offering a new way to improve responses + overcome resistance to HER2 therapies. #sabcs @oncoalert.bsky.social
Dr. Devora Isseroff shares how ctDNA monitoring in #breastcancer (TNBC & HR+) found pt anxiety remained stable in ctDNA-negative individuals. For ctDNA-positive results, physicians reported ⬇️confidence in treatment decisions, highlighting uncertainty. #SABCS25 @oncoalert.bsky.social
December 12, 2025 at 1:46 AM
Dr. Devora Isseroff shares how ctDNA monitoring in #breastcancer (TNBC & HR+) found pt anxiety remained stable in ctDNA-negative individuals. For ctDNA-positive results, physicians reported ⬇️confidence in treatment decisions, highlighting uncertainty. #SABCS25 @oncoalert.bsky.social
Drs. Jiawei Dai & Lajos Pusztai show TCGA/BEAUTY data #SABCS25, germline changes hit cell cycle/DNA repair/telomeres, somatic mutations affect adhesion/metabolism/signaling. Their CanSys tool visualizes these pathway disruptions per patient. @oncoalert.bsky.social
December 12, 2025 at 1:44 AM
Drs. Jiawei Dai & Lajos Pusztai show TCGA/BEAUTY data #SABCS25, germline changes hit cell cycle/DNA repair/telomeres, somatic mutations affect adhesion/metabolism/signaling. Their CanSys tool visualizes these pathway disruptions per patient. @oncoalert.bsky.social
Ismail Ajjawi @yaleschoolofmed.bsky.social ’27 presents data on premenopausal women with early-stage HR+/HER2– node-negative #breastcancer at #SABCS25
• Chemo use ⬇️ 35%→24%
• 72% omitted chemo, w/no difference in 5-yr OS
@oncoalert.bsky.social @sabcs.bsky.social @maryamlustberg.bsky.social
• Chemo use ⬇️ 35%→24%
• 72% omitted chemo, w/no difference in 5-yr OS
@oncoalert.bsky.social @sabcs.bsky.social @maryamlustberg.bsky.social
December 12, 2025 at 1:43 AM
Ismail Ajjawi @yaleschoolofmed.bsky.social ’27 presents data on premenopausal women with early-stage HR+/HER2– node-negative #breastcancer at #SABCS25
• Chemo use ⬇️ 35%→24%
• 72% omitted chemo, w/no difference in 5-yr OS
@oncoalert.bsky.social @sabcs.bsky.social @maryamlustberg.bsky.social
• Chemo use ⬇️ 35%→24%
• 72% omitted chemo, w/no difference in 5-yr OS
@oncoalert.bsky.social @sabcs.bsky.social @maryamlustberg.bsky.social
At #SABCS25, Dr. Julian Lin and Dr. Lajos Pusztai report that #breastcancer genes with frequent copy number amplifications and membrane protein overexpression may represent new #ADC targets.
@oncoalert.bsky.social @sabcs.bsky.social
@oncoalert.bsky.social @sabcs.bsky.social
December 11, 2025 at 8:15 PM
At #SABCS25, Dr. Julian Lin and Dr. Lajos Pusztai report that #breastcancer genes with frequent copy number amplifications and membrane protein overexpression may represent new #ADC targets.
@oncoalert.bsky.social @sabcs.bsky.social
@oncoalert.bsky.social @sabcs.bsky.social
@maryamlustberg.bsky.social presents #REPOWER at #SABCS25 —an intl study of pts with stage II/III HR+/HER2- early #breastcancer receiving adjuvant ribociclib + endocrine therapy.
@oncoalert.bsky.social @sabcs.bsky.social
@oncoalert.bsky.social @sabcs.bsky.social
December 11, 2025 at 8:13 PM
@maryamlustberg.bsky.social presents #REPOWER at #SABCS25 —an intl study of pts with stage II/III HR+/HER2- early #breastcancer receiving adjuvant ribociclib + endocrine therapy.
@oncoalert.bsky.social @sabcs.bsky.social
@oncoalert.bsky.social @sabcs.bsky.social
Dr. Eric Winer at #SABCS25 reframed how to think about #breastcancer subsets and reminded attendees that #DCIS treatment depends on clear patient education and patient-led decisions. “There is not simply a right choice.”
@sabcs.bsky.social
@sabcs.bsky.social
December 11, 2025 at 8:11 PM
Dr. Eric Winer at #SABCS25 reframed how to think about #breastcancer subsets and reminded attendees that #DCIS treatment depends on clear patient education and patient-led decisions. “There is not simply a right choice.”
@sabcs.bsky.social
@sabcs.bsky.social
Reposted by Yale Cancer Center
The S2409 PRISM trial biomarker-tests patients with extensive stage small cell #LungCancer during induction treatment and assigns them to 1 of 3 maintenance therapy cohorts based on #SCLC subtype and SLFN11 status. #LCSM
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409
December 11, 2025 at 1:40 PM
The S2409 PRISM trial biomarker-tests patients with extensive stage small cell #LungCancer during induction treatment and assigns them to 1 of 3 maintenance therapy cohorts based on #SCLC subtype and SLFN11 status. #LCSM
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409
Dr. Jack Robbins shares new data from @yalepathology.bsky.social showing that HER2 measured by Troplex™ is linked to longer benefit from T-DXd, while higher TROP2 surprisingly predicts shorter response #SABCS25.
@sabcs.bsky.social @oncoalert.bsky.social
@sabcs.bsky.social @oncoalert.bsky.social
December 11, 2025 at 3:06 PM
Dr. Jack Robbins shares new data from @yalepathology.bsky.social showing that HER2 measured by Troplex™ is linked to longer benefit from T-DXd, while higher TROP2 surprisingly predicts shorter response #SABCS25.
@sabcs.bsky.social @oncoalert.bsky.social
@sabcs.bsky.social @oncoalert.bsky.social
Dr. Mariya Rozenblit highlights how C1D15 DiviTum® TKa levels can uncover early adherence issues or drug interactions during CDK4/6 inhibitor therapy. #SABCS25 Takeaway: DiviTum® TKa is a practical early biomarker to optimize breast cancer treatment outcomes.
@sabcs.bsky.social
@sabcs.bsky.social
December 11, 2025 at 1:23 PM
Dr. Mariya Rozenblit highlights how C1D15 DiviTum® TKa levels can uncover early adherence issues or drug interactions during CDK4/6 inhibitor therapy. #SABCS25 Takeaway: DiviTum® TKa is a practical early biomarker to optimize breast cancer treatment outcomes.
@sabcs.bsky.social
@sabcs.bsky.social
New research from Dr. Lajos Pusztai #SABCS25 shows RNA levels of ESR1, PGR closely match traditional estrogen receptor/progesterone receptor test results in #breastcancer. @foundationmedicine.bsky.social @sabcs.bsky.social
@oncoalert.bsky.social
@oncoalert.bsky.social
December 11, 2025 at 1:20 PM
New research from Dr. Lajos Pusztai #SABCS25 shows RNA levels of ESR1, PGR closely match traditional estrogen receptor/progesterone receptor test results in #breastcancer. @foundationmedicine.bsky.social @sabcs.bsky.social
@oncoalert.bsky.social
@oncoalert.bsky.social
Dr. Guannan Gong shares how an #AI-driven patient-matching system improved ID of eligible patients for #breastcancer trials + increased representation of under-enrolled groups. #SABCS25
@maryamlustberg.bsky.social
@sabcs.bsky.social
@oncoalert.bsky.social
@maryamlustberg.bsky.social
@sabcs.bsky.social
@oncoalert.bsky.social
December 11, 2025 at 1:17 PM
Dr. Guannan Gong shares how an #AI-driven patient-matching system improved ID of eligible patients for #breastcancer trials + increased representation of under-enrolled groups. #SABCS25
@maryamlustberg.bsky.social
@sabcs.bsky.social
@oncoalert.bsky.social
@maryamlustberg.bsky.social
@sabcs.bsky.social
@oncoalert.bsky.social
Dr. Tristan Jordan shows how invasive lobular carcinoma #ILC + invasive ductal carcinoma #IDC #breastcancer respond differently to neoadjuvant therapy: ILC shows poorer response in TNBC but similar outcomes in ER+/HER2– & HER2+ subtypes. #SABCS25
@yalepathology.bsky.social
@oncoalert.bsky.social
@yalepathology.bsky.social
@oncoalert.bsky.social
December 11, 2025 at 1:15 PM
Dr. Tristan Jordan shows how invasive lobular carcinoma #ILC + invasive ductal carcinoma #IDC #breastcancer respond differently to neoadjuvant therapy: ILC shows poorer response in TNBC but similar outcomes in ER+/HER2– & HER2+ subtypes. #SABCS25
@yalepathology.bsky.social
@oncoalert.bsky.social
@yalepathology.bsky.social
@oncoalert.bsky.social